FDA018 Antibody Drug Conjugate
- Generic Name
- FDA018 Antibody Drug Conjugate
FDA018-ADC vs Investigator's Choice Chemotherapy to Treat Locally Advanced, Recurrent or Metastatic Triple-negative Breast Cancer
Phase 3
Not yet recruiting
- Conditions
- Triple Negative Breast Cancer
- Interventions
- First Posted Date
- 2024-07-25
- Last Posted Date
- 2024-07-25
- Target Recruit Count
- 350
- Registration Number
- NCT06519370
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
A Study of FDA018-ADC in Patients with Advanced Solid Tumors
Phase 1
Active, not recruiting
- Conditions
- Advanced/ Metastatic Solid Tumors
- Interventions
- First Posted Date
- 2022-01-03
- Last Posted Date
- 2025-03-10
- Target Recruit Count
- 78
- Registration Number
- NCT05174637
- Locations
- 🇨🇳
Fudan University Shanghai Cancer Center, Shanghai, Shanghai, China
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath